Riverbridge Partners LLC Trims Stock Position in Stevanato Group S.p.A. (NYSE:STVN)

Riverbridge Partners LLC lessened its holdings in Stevanato Group S.p.A. (NYSE:STVN - Free Report) by 10.2% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,025,197 shares of the company's stock after selling 116,856 shares during the period. Riverbridge Partners LLC's holdings in Stevanato Group were worth $22,339,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of STVN. nVerses Capital LLC purchased a new stake in Stevanato Group in the 3rd quarter worth $84,000. Hardy Reed LLC boosted its holdings in shares of Stevanato Group by 8.2% during the 3rd quarter. Hardy Reed LLC now owns 11,077 shares of the company's stock valued at $222,000 after purchasing an additional 840 shares during the last quarter. Lindenwold Advisors INC boosted its holdings in shares of Stevanato Group by 13.5% during the 3rd quarter. Lindenwold Advisors INC now owns 11,930 shares of the company's stock valued at $239,000 after purchasing an additional 1,415 shares during the last quarter. Raymond James Trust N.A. boosted its holdings in shares of Stevanato Group by 22.6% during the 3rd quarter. Raymond James Trust N.A. now owns 12,556 shares of the company's stock valued at $251,000 after purchasing an additional 2,317 shares during the last quarter. Finally, Captrust Financial Advisors boosted its holdings in shares of Stevanato Group by 12.7% during the 3rd quarter. Captrust Financial Advisors now owns 13,100 shares of the company's stock valued at $262,000 after purchasing an additional 1,480 shares during the last quarter.

Stevanato Group Trading Down 0.7 %

Shares of NYSE:STVN traded down €0.14 ($0.15) during trading on Thursday, reaching €21.38 ($22.27). The company's stock had a trading volume of 143,565 shares, compared to its average volume of 281,190. The company has a current ratio of 1.81, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22. Stevanato Group S.p.A. has a 12 month low of €16.56 ($17.25) and a 12 month high of €34.73 ($36.18). The firm's 50 day simple moving average is €21.38 and its two-hundred day simple moving average is €20.46. The stock has a market capitalization of $6.47 billion, a PE ratio of 45.49, a price-to-earnings-growth ratio of 7.68 and a beta of 0.56.

Stevanato Group (NYSE:STVN - Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The company reported €0.12 ($0.13) EPS for the quarter, missing analysts' consensus estimates of €0.13 ($0.14) by (€0.01) (($0.01)). Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The business had revenue of €277.90 million during the quarter, compared to the consensus estimate of €274.36 million. During the same period in the previous year, the business posted $0.16 EPS. The firm's revenue was up 2.4% on a year-over-year basis. On average, research analysts predict that Stevanato Group S.p.A. will post 0.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

STVN has been the subject of several research reports. Wolfe Research initiated coverage on shares of Stevanato Group in a report on Friday, December 13th. They set an "outperform" rating and a $28.00 price objective for the company. Morgan Stanley reissued an "equal weight" rating and set a $23.00 price objective (down previously from $24.00) on shares of Stevanato Group in a report on Tuesday, December 3rd. Finally, Bank of America increased their price objective on shares of Stevanato Group from $24.00 to $26.00 and gave the company a "buy" rating in a report on Friday, December 13th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of €28.60 ($29.79).

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.